What is the approximate price of each tube or box of Datopotamab?

Datopotamab deruxtecan is a new type of antibody drug conjugate (ADC), mainly used to treat recurrent or metastatic solid tumors, especially in non-small cell lung cancer and breast cancer, showing positive clinical prospects. As an innovative targeted drug, it combines monoclonal antibodies and cytotoxic carriers to achieve "precision attack" by accurately identifying tumor cell surface markers (such asTROP2). At present, this drug is still in a relatively new commercialization stage globally, so its price is relatively high, especially in the self-pay market.

In the international market, the clinical preparations of Datopotamab mostly appear in the form of dry powder or concentrated liquid for injection. The common specifications are 100mg/ bottles. According to data from some US pharmaceutical platforms, the price of each bottle (100mg) ranges from approximately 4,700 to 4,900 US dollars, which is approximately 3.3 yuan in RMB. Since the dosage of each patient needs to be calculated based on body weight, a single dose usually requires multiple bottles to be used together, so the cost of a single treatment often exceeds 10 RMB. Depending on the treatment cycle arrangement, a complete course of treatment may cost millions of yuan.

Currently, Datopotamab has not been officially launched in mainland China, nor has it been included in the scope of medical insurance reimbursement. Therefore, patients who want to use the drug mostly rely on overseas purchase channels or obtain the drug through international clinical trials. Although there is no generic version, pharmaceutical companies may reduce the financial burden on patients through patient assistance programs (PAP) or participation in research studies. Therefore, patients who need medicines should understand in advance how to obtain medicines and possible cost support.

Generally speaking, the high price of dabrotuzumab is mainly due to its high research and development costs, scarcity of indications, and significant therapeutic effects. Although the price is less affordable for most patients, for certain tumor types it may be an important option to improve survival. If the drug is approved for marketing in China and included in medical insurance in the future, patients' actual expenditures are expected to drop significantly. It is currently recommended that patients have in-depth communication with professional doctors to assess clinical necessity and explore legal and compliant drug purchase channels.

Reference materials:https://www.drugs.com/